Friday 28 July marks the World Health Organization's (WHO) World Hepatitis Day — an opportunity "to add momentum to all efforts to all efforts to implement the WHO's global health sector strategy on hepatitis for 2016–2021 and help countries achieve the final goal — to eliminate hepatitis." Read The Pharmaceutical Journal's special report on tackling this group of diseases.
Hepatitis C: tackling the silent killerSubscription
About 200,000 people are living with hepatitis C in the UK, but it is estimated that around half of these remain undiagnosed. Identifying those at risk, offering tests and connecting those infected with treatment are crucial to tackling the disease.
Substance misuse and needle exchange patients in Newcastle will be given “up to £25 of Greggs vouchers” if they present for a blood spot test for hepatitis C in a community pharmacy.
Testing individuals with any risk factor for the hepatitis C virus is more cost effective than restricting screening to people with a history of injecting drugs, a study based in the Isle of Wight has found.
Community pharmacists could be involved in detecting undiagnosed cardiovascular disease under plans laid out in the ‘The Community Pharmacy Contract Framework for 2019/20 to 2023/24’.
Deaths from liver disease related to serious hepatitis C fell by more than 16% between 2015 and 2017, according to data published by Public Health England.
Incidence of hepatitis C has fallen by almost 70% in HIV positive men who have sex with men living in London since 2015, according to research presented at a major HIV conference.
Study shows needle and syringe programmes reduce transmission of hepatitis C while delivering cost savings.
Results of a four-month pilot project show that more than half of patients using pharmacy-based needle exchange services tested positive for hepatitis C antibodies.
A “radical change” in the health service’s response to the hepatitis C virus among people who inject drugs is required if NHS England’s target to eliminate the disease by 2025 is to be met.